Skip to main content
Normal View

Medicinal Products Availability

Dáil Éireann Debate, Tuesday - 16 October 2018

Tuesday, 16 October 2018

Questions (390)

Eamon Ryan

Question:

390. Deputy Eamon Ryan asked the Minister for Health if the drug osimertinib will be made available to persons with EGFR-positive non-small cell lung cancer; the cost-benefit analysis undertaken regarding the provision of the drug; and the reason it is not available here in view of the fact that it is widely available across the EU. [41956/18]

View answer

Written answers

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the pricing and reimbursement of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Top
Share